DrugPatentWatch Database Preview
Details for Patent: RE46965
» See Plans and Pricing
Which drugs does patent RE46965 protect, and when does it expire?
Patent RE46965 protects HALAVEN and is included in one NDA.
This patent has thirty-eight patent family members in fourteen countries.
Summary for Patent: RE46965
| Title: | Intermediates for the preparation of analogs of Halichondrin B |
| Abstract: | The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4). ##STR00001## |
| Inventor(s): | Austad; Brian (Tewksbury, MA), Chase; Charles E. (Londonderry, NH), Fang; Francis G. (Andover, MA), Calkins; Trevor (Stoughton, WI), Lewis; Bryan M. (North Brunswick, NJ) |
| Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
| Application Number: | 13/924,892 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent RE46965
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE46965
| PCT Information | |||
| PCT Filed | June 03, 2005 | PCT Application Number: | PCT/US2005/019669 |
| PCT Publication Date: | December 15, 2005 | PCT Publication Number: | WO2005/118565 |
International Family Members for US Patent RE46965
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005250487 | Start Trial | |||
| Canada | 2567984 | Start Trial | |||
| Canada | 2822994 | Start Trial | |||
| Canada | 2935786 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
